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Abstract
 
Interferon (IFN)-
 
 
 
/
 
 
 
 and interleukin (IL)-12 are cytokines critical in defense against viruses, but
their cellular sources and mechanisms of regulation for in vivo expression remain poorly charac-
terized. The studies presented here identified a novel subset of dendritic cells (DCs) as major pro-
ducers of the cytokines during murine cytomegalovirus (MCMV) but not lymphocytic chorio-
 
meningitis virus (LCMV) infections. These DCs differed from those activated by 
 
Toxoplasma
 
antigen but were related to plasmacytoid cells, as assessed by their CD8
 
 
 
 
 
Ly6G/C
 
 
 
CD11b
 
 
 
phenotype. Another DC subset (CD8
 
 
 
 
 
Ly6G/C
 
 
 
CD11b
 
 
 
) also contributed to IL-12 produc-
tion in MCMV-infected immunocompetent mice, modestly. However, it dramatically in-
creased IL-12 expression in the absence of IFN-
 
 
 
/
 
 
 
 functions. Conversely, IFN-
 
 
 
/
 
 
 
 produc-
tion was greatly reduced under these conditions. Thus, a cross-regulation of DC subset
cytokine responses was defined, whereby secretion of type I IFNs by CD8
 
 
 
 
 
 DCs resulted in
responses limiting IL-12 expression by CD11b
 
 
 
 DCs but enhancing overall IFN-
 
 
 
/
 
 
 
 produc-
tion. Taken together, these data indicate that CD8
 
 
 
 
 
Ly6G/C
 
 
 
CD11b
 
 
 
 DCs play important
roles in limiting viral replication and regulating immune responses, through cytokine produc-
tion, in some but not all viral infections. They also illustrate the plasticity of cellular sources for
innate cytokines in vivo and provide new insights into the roles of IFNs in shaping immune re-
sponses to viruses.
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Introduction
 
Type I IFN-
 
 
 
/
 
 
 
 and IL-12 are innate cytokines which can
be induced early during certain viral infections. They play
critical roles in defense against viruses through antimicro-
bial as well as immunoregulatory effects (1). Biologically
active IL-12p70 protein is a heterodimer composed of an
inducible subunit (IL-12p40) and of a subunit (IL-12p35)
expressed constitutively in certain cell types but regulated
in others (2). The IFN-
 
 
 
/
 
 
 
 family consists of one IFN-
 
 
 
and multiple IFN-
 
 
 
 cytokines that bind a unique receptor
and trigger the same intracellular signaling cascades with
activation of the signal transducer and activator of tran-
scription (STAT)
 
*
 
-1 molecule. Early production of IFN-
 
 
 
and IFN-
 
 
 
4 can promote the subsequent expression of dis-
tinct IFN-
 
 
 
 genes by a positive feedback mechanism (3). In
contrast, high concentrations of IFN-
 
 
 
/
 
 
 
 inhibit the pro-
duction of IL-12 (4–8). Thus, mechanisms are in place to
differentially regulate IFN-
 
 
 
/
 
 
 
 and IL-12 responses.
 
Dendritic cells (DCs) are the most efficient APCs because
they activate T lymphocytes at low concentrations of anti-
gen and APC/lymphocyte ratios. Mouse DCs can be char-
acterized by the expression of CD11c and divided in two
 
major subsets: CD8
 
 
 
 
 
 versus CD11b
 
 
 
 (9). CD8
 
 
 
 
 
 and
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activator of transcription. 
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CD11b
 
 
 
 DCs can share a common precursor and do not
necessarily belong to distinct lineages (for a review, see refer-
ence 10). However, these subsets have been reported to play
different roles in the polarization of adaptive immune re-
sponses (10, 11). In addition, CD8
 
 
 
 
 
 but not CD8
 
 
 
 
 
 DCs
have been shown recently to produce IFN-
 
 
 
/
 
 
 
 in vitro in
response to poly(I:C) and CpG-containing oligonucleotides
(12). Although a variety of cell types can be induced to ex-
press IFN-
 
 
 
/
 
 
 
, a new subset of immature DCs character-
ized by a plasmacytoid morphology and the expression of a
specific array of membrane markers has emerged as a unique
source for high level production of the cytokines upon vi-
rus-type challenges in vitro in the human (for a review, see
reference 10) and in the mouse (13). DCs have been shown
to be producers of IL-12 under various conditions of im-
mune activation in vitro as well as in vivo (14), including
stimulation with 
 
Toxoplasma gondii
 
 soluble tachyzoite anti-
gen (STAg) (15). Macrophages (16–18) and neutrophils (19–
21) can also produce the cytokine. Little is known, how-
ever, about the cellular sources of IFN-
 
 
 
/
 
 
 
 and IL-12 and
the pathways for their regulation during productive viral in-
fections in vivo. In particular, whether plasmacytoid DCs
are important for IFN-
 
 
 
/
 
 
 
 responses after viral challenges is
not clear, because all virus-infected cells have the potential
to produce the cytokines and cell types other than DCs are
primary targets for infection with many viruses.
Innate immune responses to murine cytomegalovirus
(MCMV) and lymphocytic choriomeningitis virus (LCMV)
are being extensively studied in our laboratory. The IFN-
 
 
 
/
 
 
 
cytokines are detected early and contribute to protection
in both systems (1). In contrast, innate IL-12 responses are
limited to MCMV challenges (22–24) where they are also
necessary for optimal protection (1, 25, 26). The studies
presented here were undertaken to characterize the cellular
sources of IFN-
 
 
 
/
 
 
 
 and IL-12 during infections with
MCMV or LCMV, as well as the effects of IFN-
 
 
 
/
 
 
 
 on
their own expression and on IL-12 production during
MCMV infections. CD8
 
 
 
 
 
Ly6G/C
 
 
 
 DCs are shown to be
major producers of IFN-
 
 
 
/
 
 
 
 early after MCMV but not
LCMV infections. The same DC subset is identified as an
important contributor to IL-12 responses during MCMV
infections. Interestingly, these cells differ from the DC sub-
set producing IL-12 in response to STAg. Finally, IFN-
 
 
 
/
 
 
 
are shown to regulate DC cytokine production by enhanc-
ing their own expression while inhibiting IL-12 synthesis
during MCMV infection. Taken together, these results
demonstrate that DCs are an important source of IFN-
 
 
 
/
 
 
 
in some but not all viral infections, and that there is a plas-
ticity of cellular sources for innate cytokines production.
They also provide new insights into mechanisms by which
IFNs regulate immune responses during viral infections.
 
Materials and Methods
 
Mice.
 
E26 mice (27), 129 mice deficient for the IFN-
 
 
 
/
 
 
 
 re-
ceptor (IFN-
 
 
 
/
 
 
 
R
 
 
 
/
 
 
 
) and C57BL6 mice deficient for the
STAT-1 molecule (STAT-1
 
 
 
/
 
 
 
) were bred under pathogen-free
conditions by brother-to-sister mating in the animal care facility
 
at Brown University, Providence, RI. They were maintained on
sterile food, water, and caging. Specific pathogen free wild-type
129 (129SvEv TacFBR), 129 recombination activation gene
(RAG)-2M (129S6/SvEvTac-
 
Rag2
 
tm1
 
), and 129 STAT-1
 
 
 
/
 
 
 
(129S6/SvEv-
 
Stat
 
tm1
 
), mice were purchased from Taconic Farms.
All mice used in experiments were 5–12 wk in age. Animals ob-
tained from sources outside of Brown University were housed in
our facility at least 1 wk before use. Handling of mice and exper-
imental procedures were conducted in accordance with institu-
tional guidelines for animal care and use.
 
In Vivo Treatments.
 
Infections were initiated on day 0 by in-
traperitoneal injection of 5 
 
 
 
 10
 
4
 
 or 10
 
4
 
 plaque forming units
(PFUs) of salivary gland-extracted MCMV Smith strain or 2 
 
 
 
10
 
4
 
 PFUs of LCMV Armstrong clone E350. In vivo stimulations
with STAg were performed by intraperitoneal injection of 20 
 
 
 
g
of antigen in 500 
 
 
 
l of PBS 1
 
 
 
. Depletion of NK cells using
anti-NK1.1 or anti–AGM-1 antibodies were performed as pub-
lished elsewhere (28). The anti-Ly6G/C antibody (RB6–8C5)
and the control antibody (GL113) were produced in high density
culture conditions in Protein Free Medium II (Life Technolo-
gies), supplemented with 2 mM 
 
L
 
-glutamine and 80 
 
 
 
g/ml gen-
tallin. For experiments evaluating the contribution of Ly6G/C
 
 
 
cells to IFN-
 
 
 
/
 
 
 
 production in vivo during viral infection, mice
were injected intraperitoneally with 500 
 
 
 
g of RB6–8C5 or
GL113 (control antibody) at day 2.5 and day 0.5 before infection.
Mice were anesthetized and bled before sacrifice for organ har-
vest, at day 1.5 after MCMV infection, at day 2 after LCMV in-
fection, or at 6 h after STAg injection. Serum was prepared from
whole blood by centrifugation at 6,000 rpm for 30 min at 4
 
 
 
C.
 
Preparation of Cell Suspensions.
 
Spleens were digested by col-
lagenase (liberase
 
TM
 
 CI, Boehringer Mannheim) (29) and teased
apart by repeating pipeting in PBS 1
 
 
 
, 5 mM EDTA, and 5%
FCS (PBS/EDTA/FCS). Erythrocytes were osmotically lysed by
ammonium chloride treatment. Thereafter, cell suspensions were
kept in PBS/EDTA/FCS unless specified otherwise.
 
Enrichment for Specific Cell Subsets Using Magnetic Beads.
 
In
brief, for enrichment of specific cell subsets, splenic leukocyte
suspensions were pooled, resuspended at a concentration 
 
 
 
2.5 
 
 
 
10
 
8
 
 cells per milliliter and blocked for 15 min by incubation with
50 
 
 
 
g/ml of 2.4G2 antibody. For enrichment of macrophage
populations, cells were further incubated for 15 min with FITC-
labeled F4/80 or MOMA-1 antibodies (Serotec). Cell suspensions
were enriched by using anti-CD11c, anti-CD8
 
 
 
, anti-CD11b, or
anti-FITC magnetic beads and positive selection columns MS
 
 
 
accordingly to the instructions of the manufacturer (Miltenyi
Biotec). In some experiments, the flow through was also col-
lected to retrieve cells negative for the selection marker. CD8
 
 
 
 
 
DCs were enriched from 129 RAG-2M or E26 mice by using a
single step purification with CD8
 
 
 
 magnetic beads, because these
mice lack CD8 T lymphocytes. The enriched populations con-
tained 85–95% of cells positive for the selection marker, in con-
sistency with reports by other researchers (29).
 
Flow Cytometric Analyses.
 
Cell surface stainings were per-
formed in PBS/EDTA/FCS unless stated otherwise, after block-
ing with PBS 1
 
 
 
, 20% FCS, 10% goat serum, and 5 
 
 
 
g/ml
2.4G2. A two step protocol was used involving a first incubation
with a biotinylated antibody (anti-CD11c or anti-Ly6G/C) and a
second incubation with streptavidin-PerCP and various combina-
tions of directly conjugated mAbs among the following: CD8
 
 
 
-
APC, CD8
 
 
 
-FITC, CD11b-APC, CD11b-FITC, CD11c-PE,
F4/80-FITC, MOMA-1-FITC, Ly6G/C-APC, or correspond-
ing isotype controls. Cells were fixed in 2% paraformaldehyde for
20 min, washed, and resuspended at 
 
 
 
10
 
7
 
 cells per milliliter be- 
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fore acquisition. Macrophages were defined as F4/80
 
 
 
CD11c
 
 
 
cells, CD11b
 
 
 
GR-1
 
 
 
/low
 
CD11c
 
 
 
 cells, and MOMA-1
 
 
 
 cells,
neutrophils as CD11b
 
high
 
GR-1
 
high
 
 cells, and DCs as CD11c
 
 
 
CD8
 
 
 
 
 
, CD11c
 
 
 
CD11b
 
 
 
, and CDL
 
 
 
Ly6G/C
 
 
 
 cells. Freshly
isolated cells were evaluated for spontaneous ex vivo intracellular
expression of IL-12 using an adapted protocol (30), without any
culture step or brefeldin treatment, and with PBS 1
 
 
 
, 5 mM
EDTA, 0.5% BSA, and 0.1% sodium azide as staining buffer.
Briefly, cells were stained for three extracellular markers using
FITC, APC, and PerCP fluorochromes. After fixation, cells were
permeabilized with 1% saponin in staining buffer, blocked with
0.3 mg/ml rat IgG, and labeled with PE-conjugated anti–IL-12
antibody or control PE-conjugated rat IgG1. Acquisition was per-
formed within 4 h of completion of the stainings.
All antibodies but F4/80 and MOMA-1 were purchased from
BD PharMingen. Goat serum and rat IgG were obtained from
Sigma-Aldrich. Samples were acquired using a FACSCalibur™
(Becton Dickinson), with the CELLQuest™ v3.1 software pack-
age. Laser outputs were 15 mW at 488 and 635 nm wavelengths.
At least 100,000 events were collected within the leukocyte gate
for analysis.
 
Purification of DC Subsets by FACS
 
®
 
.
 
DC subsets were puri-
fied from total CD11c
 
 
 
 cells by fluorescence-activated cell sort-
ing using a FACSCalibur™ or a FACSVantage™ with a 70-
 
 
 
m
nozzle. In brief, CD11c
 
 
 
 cells sorted by magnetic beads were
stained with Ly6G/C-FITC, CD11c-PE, and CD8
 
 
 
-APC. A
first gate was defined based on FSC and SSC parameters, positiv-
ity for PE signals and lack of autofluorescence (negativity for
PerCP signal). Sort gates were defined within that population for
FITC and/or APC positive versus negative cells. Live cells were
then sorted accordingly to the recommendations of the manufac-
turer (Becton Dickinson). The purity and viability of the sorted
population were analyzed immediately after sorting.
 
Quantitation of IL-12 and IFN-
 
 
 
/
 
 
 
 In Sera and Conditioned Me-
dia.
 
Conditioned media (CM) were prepared by plating 10
 
5
 
–
10
 
6
 
 cells per well of a 96-well flat-bottomed tissue culture plate in
10% FCS-RPMI 1640 medium. After 24-h incubation at 37
 
 
 
C
5% CO
 
2
 
, plates were centrifuged 5 min at 1,300 rpm and super-
natants were harvested and tested directly in ELISA or frozen at
 
 
 
20
 
 
 
C for later titration. Commercial sandwich ELISA kits were
used for both IL-12p40 and IL-12p70 (R&D Systems), as well as
a custom antibody pair for IL-12p40 as described previously (24).
Limits of detection were 20 pg/ml for IL-12p40 and 7 pg/ml for
IL-12p70. For IFN-
 
 
 
 ELISA, the primary antibody was a rat
anti–mouse IFN-
 
 
 
 mAb (F-18; Hycult Biotechnology, distrib-
uted by Cell Sciences), the secondary antibody a rabbit anti–
mouse IFN-
 
 
 
 polyclonal Ab (PBL Biomedical Laboratories), the
tertiary antibody a horseradish peroxidase–conjugated donkey
anti–rabbit F(ab
 
 
 
)
 
2
 
 Ab (Jackson ImmunoResearch Laboratories);
the substrate was ABTS Peroxidase Substrate (KPL) and the stan-
dard a recombinant mouse IFN-
 
 
 
A from PBL Biomedical Labo-
ratories. This IFN-
 
 
 
 ELISA detects both recombinant mouse
IFN-
 
 
 
 (HyCult Biotechnology) and IFN-
 
 
 
A, but not IFN-
 
 
 
(PBL Biomedical Laboratories) or IFN-
 
 
 
. Colorimetric changes
of enzyme substrates were detected at 405 nm wavelength using a
SpectraMax 250 reader (Molecular Devices). In some experi-
ments, IFN-
 
 
 
/
 
 
 
 levels in sera or CM were determined in a bio-
assay as published elsewhere (23). Cytokine titers were expressed
as pg/ml or ng/ml for 10
 
6
 
 cells. Limits of detection were 1,500
pg/ml for IFN-
 
 
 
 and 8 U/ml for IFN-
 
 
 
/
 
 
 
.
 
RT-PCR for IFN-
 
 
 
/
 
 
 
 mRNA.
 
Total RNA was extracted
from 
 
 
 
5 
 
 
 
 10
 
6
 
 cells as described previously (18) and subjected to
DNase treatment using the “DNA-free” Kit (Ambion Inc.). After
 
inactivation of the DNase, 1–2  g RNA was reverse transcribed
into c-DNA by using Moloney murine leukemia virus reverse
transcriptase (Life Technologies). 5  l c-DNA was used as a tem-
plate for PCR amplification using primers specific for IFN- 4,
IFN- non4, and IFN-  described in (3, 31) and synthesized by
Operon. For relative quantitation, 18S rRNA were amplified to-
gether with mRNA for type I IFNs, in the same tube, using
primers and competimers accordingly to recommendations from
the manufacturer (Ambion Inc.) as described previously (32).
Amplifications were performed in a programmable thermal cycler
(PTC-200; MJ Research) with the following cycling parameters.
IFN- 4 and IFN- non4: 32 cycles and annealing-temperature
(Tann) 55 C, IFN- : 36 cycles and Tann 56 C.
Quantitation of Viral Load. Viral loads were quantitated in
spleen and liver homogenates using NIH-3T3 cells in a standard
plaque assay as described elsewhere (28).
Immunohistochemistry and Immunohistofluorescence. Spleen sec-
tions were prepared as described previously (32) and stained for
MCMV antigens, IL-12 or IFN- /  proteins, or marginal zone
macrophages. For IL-12 and IFN- /  stainings, tissues were re-
hydrated in 0.1 M TRIS-buffer 0.1% Tween 20 (Sigma-Aldrich)
and quenched for endogenous peroxidase. Blocking for non-
specific binding was done with normal horse serum from
VECTASTAIN Quick Kit (Vector Laboratories) followed by
blocking for avidin/biotin (Vector Laboratories). The primary an-
tibodies used were polyclonal rabbit anti–mouse IFN- /  anti-
body (Lee Biomolecular Research Laboratories) or the anti–IL-12
rat mAb C15.17 produced in the laboratory. Incubations were
performed for 2 h at 37 C in a humidified chamber. Detection
was performed using the VECTASTAIN Quick Kit followed by
Vectastain substrate kit VIP (Vector Laboratories). Sections were
counterstained with methyl green (Vector Laboratories). MCMV
stainings were performed with the MOM fluorescein kit from
Vector Laboratories, using hyperimmune serum from MCMV-
infected mice as a primary antibody. Marginal zone macrophages
were stained with MOMA-1-FITC. Sections were mounted with
anti-fading medium Vectashield (Vector Laboratories). Images
were collected digitally with a single filter cube with a Spot, RT
slider camera from Diagnostics, Inc. (purchased from MVI). Im-
ages were processed for publication with AdobePhotoshop.
Statistical Analyses. Statistical analyses were performed in Mi-
crosoft Excel 5.0 (Microsoft Corporation) using Student’s two-
tailed t tests. Unless otherwise indicated, mean   standard errors
(SE) are shown.
Results
Characterization of Conditions for Optimal IL-12 and IFN- 
Responses to MCMV and LCMV Infections. Peak IL-12
and IFN- /  responses to MCMV infection are observed
in the serum and spleen at 36–40 h (day 1.5) after challenge
(23, 24, and data not shown). Experiments in C57BL/6 and
129 mice demonstrated that the cytokines were induced to
higher levels in the 129 strain (Table I). The cytokine levels
were high in E26 mice, lacking both T lymphocytes and
NK cells (27) (Table I). Responses were not affected signifi-
cantly in 129 mice depleted of NK cells as a result of in vivo
treatment with anti-NK1.1 or anti–AGM-1 antibody treat-
ments (data not shown) or lacking T and B lymphocytes as a
result of mutation of the rag-2 gene (129 RAG-2M) (Table
I). Thus, IL-12 and IFN- /  responses to MCMV are not520 IFN- /  and IL-12 Production by Dendritic Cells during MCMV Infection
dependent on T, B, or NK cell functions. High viral doses
(5   104 PFUs) elicited higher levels of IL-12 but lower
levels of IFN- . Thus cytokine responses to MCMV infec-
tion can be better studied after low dose challenges in 129
mice. Peak IFN- /  responses to LCMV infection are ob-
served in the serum and spleen  48 h (day 2) after challenge
(1, and data not shown). Similar levels of IFN-  were pro-
duced by 129 and C57BL/6 mice. As previously reported
(5, 22), IL-12 production was not detectable after LCMV
infections under these conditions. Similarly to the MCMV
system, IFN- /  responses to LCMV infections are not de-
pendent on T or NK cell functions (Table I).
Table I. Impact of T and NK Cell Functions on IL-12p40 and IFN-  Production in Mice Infected with MCMV or LCMV
Treatmenta Serum cytokine concentration (pg/ml)c
Strain Virus PFUs nb IL-12p40 IFN- 
C57BL/6 MCMV 5    104 7 1.474   279 24,297   5,742
129 MCMV 5    104 2 4,314   313 177,034   28,607
E26 MCMV 5    104 3 3,000   312 11,347   350
129 MCMV 1    104 17 2,743   1,261 361,986   110,150
E26 MCMV 1    104 8 2,023   409 89,316   34,985
129 RAG-2M MCMV  1   104 7 1,010   301 98,483   55,425
129 LCMV 2    104 12 BLDd 28,238   18,742
C57BL/6 LCMV 2    104 6 BLD 23,934   7,763
E26 LCMV 2    104 3 BLD 30,038   4,507
aMice were infected intraperitoneally for 1.5 d for MCMV or 2 d for LCMV with the indicated viral dose of PFUs.
bNumber of mice studied.
cMean   standard error. Cytokine titers were measured by ELISA as described in Materials and Methods.
dBLD, below level of detection. Serum cytokine levels were  20 pg/ml in uninfected mice (data not shown).
Figure 1. IFN- /  production
by DCs during MCMV versus
LCMV infections. Mice were in-
fected intraperitoneally for 1.5 d
with 104 PFUs MCMV, or for 2 d
with 2   104 PFUs LCMV, or vehi-
cle treated. The contribution of DCs
to IFN- /  production was then
evaluated. (A) IFN- /  (top graph,
bioassay) and IFN-  (bottom graph,
ELISA) titers in 24 h CM from
CD11c-enriched (CD11c ), unfrac-
tionated (total), and CD11c-depleted
(CD11c ) splenic leukocyte popu-
lations isolated from 129 mice. The
data shown are representative of
nine independent experiments for
MCMV and three experiments for
LCMV. The percentages of CD11c 
cells were generally  2% in CD11c 
fractions and ranged from 3–7% in
unfractionated splenic leukocytes
versus 85–95% in enriched DC pop-
ulations. BLD indicates below limit
of detection (i.e.,  1,500 pg/ml
IFN-  or  8 U/ml IFN- / ).
Similar results were obtained in
C57BL/6 mice (three experiments
for MCMV and one for LCMV).
(B) Analyses of the expression of
IFN- /  mRNA by splenic leuko-
cytes freshly isolated from day 1.5
MCMV–infected or vehicle-treated 129 mice and fractionated for CD11c expression. (C) Levels of IFN- /  production in 24 h CM from total CD11c-
enriched (CD11c ) versus CD11c CD8  -enriched (CD8  ) cell populations from day 1.5 MCMV–infected 129 RAG-2M mice. Similar results were
obtained with CD8   cells enriched from E26 mice (data not shown).521 Dalod et al.
Assessment of DC Contribution to IFN- /  Production dur-
ing MCMV and LCMV Infections. To define the contri-
bution of DCs to IFN- /  production by hematopoietic
cells from day 1.5 MCMV– or day 2 LCMV–infected
mice, cytokine titers were measured in CM from total
splenic leukocytes and subpopulations separated based on
CD11c expression (Fig. 1 A). Cytokine production was
undetectable in CM prepared with cells isolated from ani-
mals injected with vehicle only. Furthermore, although
the cytokines were readily detectable in sera and in spleen
homogenates (data not shown), no IFN- /  production
could be detected with any of the splenic leukocyte popu-
lations isolated from LCMV-infected mice (Fig. 1 A). In
contrast, the cytokines were readily detectable by both
ELISA (IFN- ) and bioassay (IFN- / ) in the CM from
total splenic leukocytes of MCMV-infected mice. The
levels of cytokines produced were much higher with the
populations enriched in CD11c  cells than with total
splenic leukocytes, and were greatly reduced after deple-
tion of the CD11c  cells. Neutrophils and macrophages
enriched from day 1.5 MCMV–infected mice did not se-
crete detectable levels of IFN- /  proteins (data not
shown). Thus, these results show that DCs are major pro-
ducers of IFN- /  during MCMV but not LCMV infec-
tions in vivo.
To determine whether specific genes of the IFN- / 
family were expressed preferentially in DCs from MCMV-
infected mice, RNA samples extracted from total, CD11c ,
and CD11c  splenic leukocyte populations were analyzed
by relative RT-PCR (Fig. 1 B). Transcripts for IFN- ,
IFN- 4, and non–IFN- 4 were all detectable in the sam-
ples from day 1.5 MCMV–infected mice, but not in those
from vehicle-treated animals. The IFN- /  mRNA to
18S rRNA ratio were higher in CD11c  cells and lower in
CD11c  cells as compared with total splenic leukocytes.
These results show that mRNA for all three subtypes of
type I IFN are expressed preferentially in DCs during
MCMV infections in vivo.
To determine whether a specific subset of DCs contrib-
uted preferentially to IFN- /  production, CD8   DCs
were enriched from MCMV-infected RAG-2M mice, lack-
ing other populations of CD8   cells (Fig. 1 B). The levels
of the cytokines produced by the CD8  DCs were further
increased over those produced by total CD11c  DCs. These
results demonstrated that DCs, especially of the CD8   sub-
set, were the major producers of IFN- /  in ex vivo cul-
tures of splenic leukocytes from MCMV-infected mice. Fur-
ther experiments were undertaken to determine whether the
CD8   DCs producing IFN- /  during MCMV infection
in vivo were related to the Ly6G/C  immature plasmacy-
toid DCs producing IFN- /  in response to viral-type chal-
lenges in vitro (13). High levels of IFN- /  were produced
by Ly6G/C  DCs ( 98% CD11c ,  95% Ly6G/C , 0.67
 g/ml IFN- , 11,000 U/ml IFN- / ) and CD8  Ly6G/
C  DCs ( 98% CD11c ,  95%CD8  Ly6G/C , 1  g/
ml IFN- , 8,500 U/ml IFN- / ) purified from MCMV-
infected mice. In contrast no or very low levels of the cyto-
kines were produced by Ly6G/C  DCs ( 99% CD11c ,
 1% Ly6G/C , IFN-  undetectable, 123 U/ml IFN- / ).
The treatment of mice with an anti-Ly6G/C antibody
before MCMV challenge depleted the majority of the
CD8  Ly6G/C CD11b  DCs (Fig. 2 A), whereas no sig-
Figure 2. Impact of in vivo depletion of Ly6G/C  cells on IFN- /  production during MCMV versus LCMV infections. (A) Flow cytometry analysis
of the percentages of CD8  Ly6G/C  cells within splenic DCs from mice uninfected, infected by MCMV or by LCMV, and untreated or injected with
anti-Ly6G/C versus control antibody. (B) Titration of IFN-  (ELISA, black bars) and IFN- /  (bioassay, gray bars) in the sera from the same mice. The
sera of the mice injected with the antibodies but uninfected were negative for IFN- /  (data not shown). The data shown are representative of three in-
dependent experiments in 129 mice for MCMV and one for LCMV. Similar results were obtained in C57BL6 mice (2 and 1 experiments, respectively).522 IFN- /  and IL-12 Production by Dendritic Cells during MCMV Infection
nificant changes where observed in the percentages of
CD11b  DCs or in the staining for marginal-zone macro-
phages in spleen sections (data not shown). This treatment
also resulted in a dramatic reduction in production of serum
IFN- /  (Fig. 2 B). The decrease in serum type I IFNs lev-
els was at least partially due to the depletion of cytokine-pro-
ducing Ly6G/C  DCs as the in vivo antibody treatment also
abrogated the ex vivo IFN- /  production in the CM from
enriched CD11c  cells (60 ng/ml IFN-  and 3,000 U/ml
IFN- /  versus 3 ng/ml, 250 U/ml). A significant increase
in viral loads was observed in mice treated with the anti-
Ly6G/C antibody as compared with those injected with
control antibody (4.48 versus 3.62 log PFU/g of spleen, P  
0.05). By contrast, although the anti-Ly6G/C treatment also
depleted the majority of the CD8  Ly6G/C CD11b  DCs
in LCMV-infected mice (Fig. 2 A), it did not reduce the
production of serum IFN- /  (Fig. 2 B). Taken together,
these results show that Ly6G/C CD8   DCs are major
producers of IFN- /  during MCMV, but not LCMV, in-
fections in vivo, and suggest that this response is important
for the control of viral replication.
Assessment of DC Contribution to IL-12 Production.
Studies evaluating IL-12p40/p70 production in culture
and IL-12p40 expression intracellularly were performed to
characterize the cells producing this cytokine. Cytokine
production was very low to undetectable in CM prepared
with cells isolated from animals injected with vehicle only.
Similarly to what was observed for IFN- / , CD11c 
cells were major producers of IL-12p40 and IL-12p70 in
ex vivo splenic leukocyte cultures from MCMV-infected
mice (Fig. 3 A). Even higher levels of IL-12 were pro-
duced by CD8   DCs enriched from RAG-2M mice
(Fig. 3 B) and by purified CD8  Ly6G/C  DCs (26 ng/
ml). Neutrophils and macrophages enriched from d1.5
MCMV-infected mice did not secrete detectable levels of
IL-12 (data not shown). These results show that DCs, es-
pecially of the CD8  Ly6G/C  subset, are the major pro-
ducers of IL-12 in ex vivo cultures of splenic leukocytes
from MCMV-infected mice.
Using flow cytometry for intracellular IL-12p40 and sev-
eral membrane markers, the DC subsets producing IL-12
after MCMV challenge were further characterized by com-
parison to those responding to STAg (15) (Fig. 4). IL-
12p40 was clearly expressed in CD11c  cells from day 1.5
MCMV–infected mice, with a staining intensity compara-
ble to that observed in response to STAg injection but with
a higher frequency of positive cells. IL-12 was not detected
in macrophages or neutrophils (data not shown). After both
STAg and MCMV challenges, the CD8   DCs were the
main producers of IL-12, but the CD11b  DCs also con-
tributed to up to one-third of the response to MCMV. In
both cases, the IL-12  DCs expressed the class II molecules
of the major histocompatibility complex (I-Ab). In contrast,
the IL-12–producing DCs elicited by MCMV, but not
STAg, expressed Ly6G/C and moderate levels of B220.
CD8  was mostly coexpressed with Ly6G/C and to a
lesser extent with B220 on IL-12  DCs, whereas CD11b
had mutually exclusive expression with CD8  and Ly6G/C.
Thus, the DCs are major producers of IL-12 in response
to MCMV challenge in vivo. However, the subsets elicited
in response to this virus are different from those activated
by STAg, with the CD8  Ly6G/C CD11b  DCs being
responsible for most of IL-12 production but the CD8  
Ly6G/C CD11b  DCs contributing as well.
IFN- /  Regulation of IL-12 Production by DCs during
MCMV Infection. The IFN- /  cytokines have been
previously reported to inhibit IL-12 production (4–8). To
characterize the cellular site of this regulation during
Figure 3. IL-12 production by DCs during MCMV infection. The
samples used and number of experiments performed are identical to those
of Fig. 1 A and C. (A) IL-12p40 and p70 titers in 24 h CM from splenic
leukocytes sorted for CD11c expression. (B) IL-12p40 titers in 24 h CM
from CD11c-enriched (CD11c ) versus CD11c CD8  -enriched
(CD8  ) cell populations from day 1.5 MCMV–infected 129 RAG-2M
mice. Limits of detection were 20 pg/ml for IL-12p40 and 7 pg/ml for
IL-12p70. Similar results were obtained with CD8   cells enriched from
E26 mice and with purified CD8  Ly6G/C  DCs from immunocompe-
tent 129 mice (data not shown).523 Dalod et al.
MCMV infection, the nature of the cells producing IL-12
was examined in 129 mice deficient for IFN- /  func-
tions as a result of either IFN- /  receptor mutation
(IFN- / R / ), STAT-1 mutation (STAT-1 / ), or
IFN- / -producing cell depletion by anti-Ly6G/C anti-
body treatment. Higher levels of IL-12p40 and IL-12p70
were produced in vivo in the sera and ex vivo in DC CM
from IFN- / R /  as compared with IFN- / R / 
mice early after MCMV infection (Table II and data not
shown). This correlated with increased percentages of DCs
producing IL-12 as assessed by intracellular staining (Table
II), whereas the cytokine could still not be detected in
neutrophils and macrophages (data not shown). The
higher IL-12 production by DCs from IFN- / R / 
mice resulted from an enhanced recruitment of the
CD11b  subset for this function, with dramatic increases
both in the percentages of CD11b  DCs producing IL-12
(Fig. 5 A and Table II) and in the mean fluorescence in-
tensity (MFI) for IL-12 staining in these cells (Fig. 5 B).
Disruption of IFN- /  functions had smaller effects on
the production of IL-12 by CD8   DCs (Fig. 5 and Table
II). As a result, CD11b  DCs became a major population
for IL-12 production in IFN- / R /  mice, with an
overall contribution equal to, or higher than, CD8   DCs
(Fig. 5). Similar results were obtained in STAT-1 /  mice
(Fig. 5 and Table II), showing that the inhibition of IFN-
 /  on IL-12 production was mediated downstream of
STAT-1–dependent events. Hence, during MCMV infec-
tion, IFN- /  responses limit IL-12 production by DCs,
with preferential regulation on the CD11b  subset. The
recruitment of cell types for IL-12 production is restricted
to DC subsets as other splenic leukocyte populations do
not appear to express the cytokine even in the absence of
IFN- /  functions.
The differences in the production of IL-12 by DC sub-
sets were not due to an intrinsic increased reactivity of
CD11b  DCs from mice deficient in IFN- /  responses,
because STAg challenge did not induce detectable expres-
sion of type I IFNs and there were no significant differ-
ences in the levels and sources of IL-12 production af-
ter STAg stimulation of IFN- / R /  mice (data not
shown). They were, however, associated with elevated
viral replication. Viral burdens were significantly in-
creased in the spleen of IFN- / R /  as compared with
wild-type mice at day 1.5 MCMV infection (5.61 vs. 4.92
log PFU/g of spleen, P   0.001). Immunohistofluores-
cence studies of splenic sections demonstrated that
MCMV antigens were primarily observed in discrete foci
within the marginal zone in IFN- / R /  mice (Fig. 6
A). IL-12 expression localized to the same areas (Fig. 6 B).
Consistent with the increased viral burden in IFN-
 / R /  mice, MCMV antigen expression extended
through a ring encompassing the marginal zone and
spreading toward both red and white pulp areas. IL-12
staining was also more intense and its pattern of distribu-
tion changed in parallel with MCMV antigens. Thus, IL-
12 is produced in vivo at the local sites of MCMV antigen
expression, and the enhanced recruitment of CD11b 
DCs for production of the cytokine in the absence of
IFN- /  responses is associated with local changes in vi-
ral loads or cell tropism.
Blocking endogenous IFN- /  production during
MCMV infection by in vivo depletion of the CD8  
Ly6G/C CD11b  DCs did not significantly affect the pro-
duction of IL-12 in serum and DC CM (Table II), al-
though these cells were a major source of IL-12 produc-
tion in immunocompetent mice. IL-12 responses were
maintained in mice treated with anti-Ly6G/C antibody as a
Figure 4. Comparative phenotypic analysis of the DC-producing IL-12
in response to STAg versus MCMV. The top dot plots show intracellular
staining for IL-12p40 in CD11c-enriched cell populations from splenic
leukocytes of 129 mice injected with vehicle or with STAg, or infected
with MCMV. Note that IL-12 is expressed only in CD11c  cells. Histo-
gram plots show the stainings with antibodies specific for various mem-
brane markers (gray area) versus isotype control (black line) within the
IL-12  DC gate. The dot plots show the relative distribution of various
pairs of membrane markers within IL-12  DC gate. Percentages of cells
within IL-12 gates, histograms markers, or dot-plot quadrants are shown
on the graphs. The data shown are representative of three independent
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result of increased production by CD11b  DCs, compen-
sating for the loss of CD8  Ly6G/C CD11b  DCs (Fig.
5 A and Table II). Taken together, these data demonstrate
the plasticity of DC responses for IL-12 production and
identify a new mechanism for cross-regulation between
DC subsets, the CD8  Ly6G/C CD11b  cells limiting
IL-12 production by the CD8 -Ly6G/C CD11b  ones
through secretion of IFN- / .
Positive Feedback Regulation of IFN- /  Production by DCs
during MCMV Infection. IFN- /  have been reported to
amplify their own expression by positive feedback (3). In-
deed, at times when MCMV replication and viral antigen
expression were increased in IFN- / R /  as compared
with IFN- / R /  mice (Fig. 6 A), IFN- /  protein
production was decreased in splenic sections (Fig. 6 C).
Significant decreases in IFN- /  levels were also observed
in the sera and in the DC CM of IFN- / R /  mice (Ta-
ble III). These results show that high level production of
IFN- /  by DCs during MCMV infection in vivo are
achieved partially through a positive immunoregulatory
feedback at the level of DC expression and not only as a di-
rect response to viral determinants. They also dissociate the
conditions optimizing IFN- /  versus IL-12 responses
during MCMV infections.
Table II. Impact of IFN- /  Functions on IL-12 Production by DC Subsets
Stain or treatment na
IL-12p40 (pg/ml) Percentage of IL-12  cells within DC subsetsb
Serab DC CMc CD11c  CD8   CD11b 
IFN- / R /  4 2,821   288 2,222 13.5   0.7 28.8   0.8 5.2   0.5
IFN- / R /  4 7,975   1,034d 8,285 20.4   2.6e 39.9   1.8d 14.3   2.4d
STAT-1 /  3 2,211   508 ND 6.7   1.9 24.4   3.7 5.5   0.7
STAT-1 /  3 4,060   152 ND 10.5   1.1g 27.4   1.5g 13.7   1.9e
Control Ab 4 2,121   498 13,064 3.8   0.7 16.1   3.0 2.8   1.1
Anti-Ly6G/C 4 2,878   226g 6,240 5.3   0.6h 8.1   1.3e 9.2   1.1d
Mice were infected intraperitoneally for 1.5 d with 104 PFUs MCMV.
Data from IFN- / R+/+ versus IFN- / R /  are from one representative experiment out of three.
aNumber of mice per group.
bMean   standard error.
c24-h CM from enriched DCs.
dP   0.001.
eP   0.005.
fP   0.01.
gNS.
hP   0.05.
Figure 5. Impact of IFN- /  functions on IL-12 production by DCs
in vivo during MCMV infection. IFN- / R / , IFN- / R / ,
STAT-1 / , STAT-1 / , untreated, control antibody-treated, or anti-
Ly6G/C-treated 129 mice were infected intraperitoneally for 1.5 d with
104 PFUs MCMV. The percentages and phenotypes of the DCs express-
ing IL-12p40 were then evaluated by flow cytometry. (A) Percentages
of IL-12  cells within DCs (CD8  CD11b  DCs: gray bars;
CD8  CD11b  DCs: black bars; and CD8  CD11b  DCs: white bars).
(B) MFI for IL-12 staining in CD8  CD11b  DCs (gray bars) versus
CD8  CD11b  DCs (black bars). The data shown are representative of
three independent experiments for IFN- / R / . Similar results were ob-
tained in STAT-1 /  mice on the C57BL6 genetic background (data not
shown). CD8  and CD11b were consistently found to have mutually exclu-
sive expression on IL-12  DCs in the experimental systems described here.525 Dalod et al.
Discussion
IFN- /  and IL-12 play critical roles for defense against
viral infections and are differentially regulated. Little is
known, however, about the cellular sources for these cy-
tokines and their regulation during viral infections in vivo.
Here, CD8  Ly6G/C CD11b  DCs are shown to be
major producers of both IL-12 and IFN- /  early after
MCMV, but not LCMV, challenges. The data presented
extend our previous reports documenting IFN- /  inhibi-
tion of IL-12 production, by also establishing that this reg-
ulatory mechanism can be mediated at the level of DC sub-
populations, with the production of IFN- /  by CD8  
DCs resulting in STAT-1–dependent responses limiting
IL-12 expression by CD11b  DCs. These studies demon-
strate the plasticity of innate cellular responses and charac-
terize key events in the shaping of these during viral infec-
tions. Taken together, they also provide new insights into
how these early events and innate responses may act to reg-
ulate downstream adaptive responses.
T, B, and NK cells were not required for IFN- /  pro-
duction in vivo during MCMV infection and spleen granu-
locytes and macrophages enriched from infected mice did
not secrete detectable levels of the cytokines. In contrast,
DCs, especially of CD8  Ly6G/C  subset, produced large
amounts of IFN- / . Furthermore, Ly6G/C  cells were
necessary for IFN- /  production in sera and DC CM.
These results suggest that CD8  Ly6G/C  DCs may be
the only producers of IFN- /  in vivo. Alternatively, they
may be the initial sources of the cytokines triggered directly
in response to virus challenge and inducing downstream ex-
pression of IFN- /  by other cell types in a positive immu-
noregulatory feedback (1, 3). Indeed, IFN- /  functions
were shown to be required for high production of the cyto-
kines, both in vivo during MCMV challenge and ex vivo
by DCs enriched from infected mice. However, the lack of
requirement of T, B, and NK cells for type I IFNs produc-
tion, the absence of detectable secretion of the cytokines by
Figure 6. Localization of MCMV antigen, IFN- / , and IL-12 in the spleen. Immunohistochemistry or immunofluorescence were performed on
spleen sections from uninfected or day 1.5–infected IFN- / R /  and IFN- / R /  mice. (A) Staining for MCMV antigen by immunofluorescence
(scale bars represents 1 mm for the larger photographs and 100  m for the inserts). (B) IL-12 and (C) IFN- /  staining by immunohistochemistry (scale
bars represents 100  m for the larger photographs and 50  m for the insert).526 IFN- /  and IL-12 Production by Dendritic Cells during MCMV Infection
cell populations enriched in macrophages and neutrophils,
and the decreased production by populations depleted of
CD11c  cells suggest that DCs are the major producers of
IFN- /  in response to MCMV infection in vivo and that
the positive feedback mechanism for the production of the
cytokines acts at the level of the DCs themselves. The major
mouse cells producing IFN- /  in response to in vitro vi-
ral challenges have been recently reported as CD11c 
CD8  Ly6G/C CD11b  plasmacytoid immature APC
(13). These cells upregulate CD8  after 24 h of culture,
particularly when exposed to viruses or other activators.
Taken together with the results presented here, the studies
suggest that activated CD8  Ly6G/C CD11b  DCs are
major producers of IFN- /  in vivo during MCMV in-
fection and that they likely derive from plasmacytoid
CD11c CD8  Ly6G/C CD11b  immature APC.
Although virtually any cell type can be induced to ex-
press IFN- /  if appropriately stimulated, MCMV infec-
tion is shown here to preferentially induce production of
these cytokines in a small subset of specialized cells, the
plasmacytoid DCs. Thus, during certain viral infections,
plasmacytoid DCs are major contributors to global IFN- / 
production and must therefore, play an important role in
any responses downstream of these cytokines (1). This may
not be a universal situation, however, because the cell types
infected or the nature of the stimuli delivered by microbial
products may result in stimulating IFN- /  production by
other populations. Indeed, challenges with inactivated her-
pes simple virus have been reported to stimulate IFN- / 
production by marginal zone macrophages (33). A striking
result presented here is that DCs do not contribute signifi-
cantly to the IFN- /  responses observed in the sera and
spleens of mice infected with LCMV Armstrong. Because
some strains of LCMV have been reported to infect DCs
(34) and the in vivo targets for MCMV replication have
not been clearly identified, further experiments will be
needed to compare these viruses for DCs tropisms in vivo,
relative to cellular sources for innate cytokine production.
Nevertheless, it is interesting to note that there is low to no
detectable IL-12 expression during infections with a variety
of LCMV isolates, including those reported to infect DCs,
under conditions inducing IFN- /  responses (unpub-
lished data). Thus, there are other reasons to believe that
the stimulation for innate cytokine responses is delivered to
different cell populations during LCMV as compared with
MCMV infections.
The characterization of CD8   DCs as major producers
of IL-12 after MCMV infection is consistent with the cell
type producing IL-12 in response to STAg challenge.
However, the CD8   DC subsets recruited in response to
MCMV differ from those activated by STAg as they ex-
press a specific array of membrane markers, in particular
Ly6G/C, linking them to the plasmacytoid IFN-producing
DCs. Indeed, the main producers of IL-12 and IFN- / 
during MCMV infection in vivo were found to belong to
the same CD8  Ly6G/C CD11b  subset of DCs. Al-
though we cannot exclude the possibility that these cells
correspond to a different maturation stage of the same DC
populations producing IL-12 in response to STAg stimula-
tion, we favor the hypothesis that they arose from different
precursors expressing different arrays of receptors for mi-
crobial products. Future studies examining the expression
of receptors, such as the Toll-like molecules, on these dif-
ferent DC subsets, as well as their function for innate cy-
tokine responses to viral infections, may help to understand
their functional specialization and ontogenic relationships.
A broader range of DC subsets was also induced to pro-
duce IL-12 during MCMV as compared with STAg chal-
lenges, including CD11b  cells, and the contribution of
this subset was dramatically increased in the absence of
IFN- /  functions. Although CD8   DCs lack the ability
to secrete IL-12 under various conditions in vitro and in
vivo (12, 14), they were recently shown to be the main
producers of this cytokine in response to heat-killed Bru-
cella abortus, in an IL-10–regulated way (35). Here, condi-
tions of antigenic stimulation and cytokine regulation are
defined, i.e., MCMV infection in the absence of IFN- / 
functions, where CD11b  DCs produce high levels of IL-
12 in vivo. As the conditions also are associated with in-
creased viral replication and spread through the spleen,
changes may occur in viral tropism in the absence of IFN-
 /  functions as reported during infections with other vi-
ruses (for a review, see reference 36). Thus, enhanced ex-
posure to virus or virus-infected cells may have contributed
to the elevated CD11b  DC production of IL-12 in IFN-
 / R /  mice. However, no changes in the level and
sources of IL-12 production were observed in mice defi-
cient for the IFN-  receptor or for the STAT-4 molecule,
even though viral replication was also increased in these
immunodeficient animals (data not shown). Furthermore,
previous studies, from our laboratory in the mouse and
from others in human systems, have shown that IFN- / 
inhibit IL-12 production in vitro in response to nonreplica-
tive stimuli such as LPS or SAC (4–8). Therefore, it is
likely that IFN- /  inhibition of IL-12 production by
CD11b  DCs in vivo during MCMV infection results at
least in part from immunoregulatory mechanisms.
Table III. Impact of IFN Functions on IFN-  Production by DCs
Strain na
IFN-  (pg/ml)
Serab DC CMc
IFN- / R /  4 382,270   11,607 40,870
IFN- / R /  4 99,430   14,181d 12,390
Mice were infected intraperitoneally for 1.5 d with 104 PFUs MCMV.
Data are from one representative experiment out of three.
aNumber of mice per group.
bMean   standard error.
c24-h CM from enriched DCs.
dP   0.001.527 Dalod et al.
In summary, we have shown that CD8  Ly6G/
C CD11b  DCs play a central role in innate immune re-
sponses to MCMV infection as major producers of IL-12
and IFN- / , both cytokines involved in the activation of
antiviral NK and T cell immune responses (36). Moreover,
our results suggest a new mechanism for cross-regulation
between DC subsets, the production of IFN- /  by the
CD8   DCs inhibiting IL-12 expression by the CD11b 
DCs. The biological consequences of these responses are
not yet completely understood but they may have multiple
effects on promoting the endogenous immune responses
most protective against MCMV infections while acting to
limit potentially detrimental responses (37). For example,
the conditions leading to high production of IL-12 by DCs
are linked to decreased production of IFN- /  and would
therefore, trigger strong NK cell IFN-  secretion but
weaker cytotoxic activity. This might be detrimental to the
host because NK killing has been shown to contribute to
defense against MCMV-induced disease and because excess
production of IL-12 can lead to cytokine-mediated disease
(36). Likewise, because CD8   DCs have been reported to
have unique capabilities for cross-priming cytotoxic T lym-
phocytes (38, 39) and CD11b  DCs may be more efficient
at activating CD4 T cells (39, 40), the responses may act to
potentially limit IL-12– and CD4 T lymphocyte-induced
immunopathology and to promote the development of
strong CD8 T cell responses. Thus, these observations pro-
vide new insights into the mechanisms by which IFN- / 
may shape innate and adaptive responses to promote health
over disease during certain viral infections.
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